Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (10938)	11/10/1997 9:16:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

chirodoc, There is a very good chance that Targretin would be put on a fast track approval. It does cause the tumor to shrink and virtually all patients respond (with a complete remision, partial remission, or stabilization of disease), even advanced cases. Once it's approved for CTCL, it can be prescribed for anything an MD deems as appropriate. FDA reforms will allow promotion of off label uses and I expect LLY to aggressively develop Targretin as well as the 2nd and 3rd generation compounds (which are tied to the lion's share of the $75 million in milkestone payments). By the time Tragretin is approved, LGND should have advanced interim clinical data from Europe as well as North America (for type II diabetes). With FDA reform in place, they will be able to show the interim data to physicians and begin off label sales. Likewise, the drug is in Phase II/III lung cancer trials which is a much bigger market and that data should come out this quarter. I expect off-label Targretin sales to be significant.